- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Vendor issues new warning on Omniscan MR contrast for patients with kidney disease
GE Healthcare warned European providers Feb. 7 to discontinue the use of gadodiamide (Omniscan) for patients who may be at risk for a rare and life-threatening skin disease.
GE Healthcare warned European providers Feb. 7 to discontinue the use of gadodiamide (Omniscan) for patients who may be at risk for a rare and life-threatening skin disease.
Nephrogenic systemic fibrosis, also known as nephrogenic fibrosing dermopathy, may occur in patients with moderate to end-stage kidney disease after an MRI or MR angiography study with gadolinium-based contrast media. NSF causes problems in the joints and in some cases quickly results in loss of mobility or death.
The manufacturer's warning is associated with a new ruling from the European Medicines Agency, the regulatory body for pharmaceuticals in the European Union. The EMEA decision was also released Feb. 7.
In line with the EMEA alert, GE advises that Omniscan is contraindicated in the following cases:
- patients with severe renal impairment (glomular filtration rate <30 mL/min)
- patients who have had a liver transplant or are awaiting liver transplantation
The manufacturer also advised caution when administering gadodiamide to neonates and infants up to one year old, again in line with EMEA guidance.
As of Feb.7, GE had received 96 reports of NSF following Omniscan administration. In most cases, high doses were administered. Although regulatory agencies have received reports of NSF following administration of other gadolinium-based MR agents, most have been linked to Omniscan, according to GE.
The company advised physicians to use general radiography and other alternative imaging techniques for patients with severely compromised renal function. Physicians can call the following numbers if they have questions or to report cases:
- in the U.S.: 1-800/654-0118
- in Europe: +44(0)1494 542612
For more information from the Diagnostic Imaging archives:
European authorities warn against use of Omniscan in at-risk patients
FDA renews warning on gadolinium in patients with weak kidneys
Gadolinium-related problems stem from one specific agent
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
